Jamjoom Pharma
جمجوم فارماTechnical Analysis & Signals
Jamjoom Pharma stock shows an upward trend with positive signals in the Saudi market.
Technical Analysis
Jamjoom Pharma stock (4015.SR) shows an upward trend with positive signals from indicators such as RSI at 62.0 and MACD Hist at 1.1927. The stock is expected to continue moving within the Bollinger range between 124.94 and 144.4.
Support & Resistance Levels
The main support level for the stock is at 134.67 SAR, while the resistance level is at 144.4 SAR. The stock may head towards testing the resistance level if the positive momentum continues.
Volume Analysis
Volume analysis indicates noticeable trading activity in the stock, reflecting investor interest. An increase in trading volume may enhance the current upward trend.
Fundamental Factors
The price-to-earnings (P/E) ratio stands at 22.3, indicating a relatively high valuation. Additionally, the dividend yield is at 2.81%, which may attract income-seeking investors.
Risk Factors
Potential risks that the stock may face include general market volatility and any changes in economic policies. These factors could impact the stock's performance in the future.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. The stock is expected to continue its upward trend, but investors should conduct their own research.
Automated analysis is based on historical data and technical indicators and may not reflect future market conditions.
Financial Fundamentals
Price Data
Price Chart - Jamjoom Pharma
4015Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Weak TrendFinancial Summary
Valuation
- Market Cap
- 9.94B
- P/E Ratio
- 22.30
- P/B Ratio
- 5.80
- EPS (Earnings/Share)
- 6.37
Profitability
- Revenue
- 1.50B
- Net Income
- 463.80M
- Return on Equity (ROE)
- +30.00%
- Shares Outstanding
- 70.00M
Balance Sheet
- Total Assets
- N/A
- Total Debt
- 16.43M
- Debt/Equity
- 0.96
- Free Float %
- +34.5%
Dividends & Margins
- Dividend Yield
- +2.81%
- Dividend/Share
- 4.00
- Book Value
- 24.48
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
4 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2024 | 1.32B +19.8% | 356.52M +21.9% | 1.77B +7.1% | 2.09M -12.8% | 5.09 +21.8% |
| 2023 | 1.10B +20.1% | 292.40M +70.7% | 1.65B +17.5% | 2.40M -8.9% | 4.18 +70.6% |
| 2022 | 916.67M +24.6% | 171.31M +0.4% | 1.41B -1.7% | 2.64M +34.0% | 2.45 +0.4% |
| 2021 | 735.68M | 170.70M | 1.43B | 1.97M | 2.44 |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
Ubhar Capital reviews Jamjoom Pharma Q4 results, maintains TP
Jamjoom Pharma used 75.1% of production capacity in 2025: CEO
Jamjoom Pharma provides SAR 31.8M corporate guarantee to Algerian JV
Jamjoom Pharma shareholders reject LTIP, buyback plan
Analysts’ views on Jamjoom Pharma Q4 2025 results, average TP
BSF Capital comments on Jamjoom Pharma Q4 results, sets TP
Jamjoom Pharma lowers revenue growth guidance for 2026, 2027
Firms likely to declare cash dividends in Feb. based on historical pattern
News source: Argaam (argaam.com)
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-03-26
Risk Assessment
Risk Factors
Average True Range 3.9% of stock price
Trading volume below 30% of average
P/E ratio 22.3
Debt-to-equity ratio 0.96
ADX indicator at 18 — no clear direction
Stable fundamentals, low volatility, and good financial solvency
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Jamjoom Pharma stock price today?
Jamjoom Pharma (4015) stock price today is 142.00 SAR, declining by -0.42% compared to the previous session close. The 52-week price range is between 123.13 SAR and 178.91 SAR.
2 What is Jamjoom Pharma stock valuation?
The automated analysis signal for Jamjoom Pharma is "Buy" with 75% confidence. The P/E ratio is 22.3. The P/B ratio is 5.80.
3 Is Jamjoom Pharma Shariah-compliant?
Yes, Jamjoom Pharma (4015) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Jamjoom Pharma dividend distributions?
Jamjoom Pharma has a dividend yield of 2.81%, with an estimated annual dividend of 4.00 SAR per share.
5 What is Jamjoom Pharma weekly performance?
Jamjoom Pharma performance over different time periods: weekly change +4.49%, monthly +8.88%, and year-to-date +0.11%. The stock is currently trading with a volume of 46,496 shares.
6 What is the target level for Jamjoom Pharma?
According to automated analysis for Jamjoom Pharma: Short-term target (1-2 weeks): 150.00 SAR. Medium-term target (1-3 months): 160.00 SAR. Support level: 134.67 SAR. Resistance level: 144.40 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.